Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q2 FY2020 Earnings Presentation
18 slides from Advanced Enzyme Technologies's earnings presentation, Nov 2, 2019
Slide 1: Advanced Enzyme Technologies Limited – Earning Presentation Q2FY20
Advanced Enzyme Technologies Limited Where ENZYME is Life Earning Presentation | Q2FY20
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview: What are enzymes?
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed integrated enzyme player globally 4,196 2nd 2nd Amongst Top 15 Global Enzyme Companies 2,321 Manufacturing Units – 7 R&D Units – 7 FY 15 FY 19 India - 5 USA - 2 I
Slide 5: Results Summary – Q1FY20 (Consolidated)
Results Summary – Q1FY20 (Consolidated) *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,114 1,032 473 421 318 259 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Bio-Processing -24% -9% (18%) 9% 7% (47%) 13% Q2FY20 129 824 161 Q2FY19 118 77
Slide 6: Revenue Split – Q2FY20
Revenue Split – Q2FY20 Q2FY20 Q2FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 14% 12% 14% 11% 74% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 2% 5% 5% 46% 49% 41% 39% 7% 5% Asia (ex- India) Ot
Slide 7: Results Summary – H1FY20
Results Summary – H1FY20 Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 2,218 1,008 2,074 905 651 571 H2FY19 H2FY20 H2FY19 H2FY20 H2FY19 H2FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Bio-Processing -24% -1% (18%) 4% 7% (47%) 10% H1FY20 261 1,630 324 H1FY19 250 1,527 294 Note
Slide 8: Revenue Split – H1FY20
Revenue Split – H1FY20 H1FY20 H1FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 15% 12% 14% 12% 73% 74% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 2% 5% 5% 45% 49% 39% 42% 7% 5% Asia (ex- India) Ot
Slide 9: Profit & Loss (Consolidated) – Q2FY20 & H1FY20
Profit & Loss (Consolidated) – Q2FY20 & H1FY20 ₹ in Million except per share data Q2FY20 Q1FY20 Q2FY19 H1FY20 H1FY19 Particulars Y-o-Y (%) Y-o-Y (%) Unaudited Unaudited Unaudited Unaudited Unaudited Income from Operations 1,114 1,103 1,032 8% 2,218 2,075 7% Expenses 706 631 663 6% 1,338 1,274 5% Pro
Slide 10: Balance Sheet (Consolidated) – H1FY20
Balance Sheet (Consolidated) – H1FY20 ₹ in Million H1FY20 H1FY19 Particulars Unaudited Unaudited Assets Property, plant and equipment 1,706 1,647 Capital work-in-progress 157 103 Intangible assets 594 677 Goodwill 2,764 2,850 Other non-current assets 185 173 Current assets 3,396 2,725 Assets held fo
Slide 11: Results Summary – FY19
Results Summary – FY19 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,196 1,159 1,819 3,957 1,640 936 FY18 FY19 FY18 FY19 FY18 FY19 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% (1%) 10% (1%) 9% FY19 493 3,133 482 FY18 498 2,860 444 Note: 1.. On Consolidated Basi
Slide 12: Revenue Split – FY18 vs FY19
Revenue Split – FY18 vs FY19 FY19 FY18 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 12% 12% 13% 76% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 1% 4% 4% 47% 50% 41% 45% 3% 3% Asia (ex- India)
Slide 13: Profit & Loss (Consolidated) – FY19
Profit & Loss (Consolidated) – FY19 ₹ in Million except per share data FY19 FY18 Particulars Y-o-Y (%) Audited Audited Income from Operations 4,196 3,957 6% Expenses 2,588 2,500 4% Profit from Operations before Other Income, Finance Costs and 1,608 1,457 10% Exceptional Item Other Income 50 14 261%
Slide 14: Balance Sheet (Consolidated) – FY19
Balance Sheet (Consolidated) – FY19 ₹ in Million FY19 FY18 Particulars Audited Audited Assets Property, plant and equipment 1,618 1,667 Capital work-in-progress 105 105 Intangible assets 622 662 Goodwill 2,715 2,584 Other non-current assets 183 143 Current assets 2,821 2,107 Assets held for sale 48
Slide 15: Strong Financial Performance – FY19
Strong Financial Performance – FY19 ₹ in Million Revenue from Operations 2,500 EBIDTA & EBIDTA Margin (%) 50% 47% 45% 48% 4,196 3,957 2,000 45% 42% 46% 3,431 1,870 2,938 1,500 42% 1,654 44% 1,534 2,321 1,000 1,389 42% 931 40% 500 38% 0 36% FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY19 E
Slide 16: Strong Financial Performance – FY19
Strong Financial Performance – FY19 Net Working Capital (Days) Net Worth (₹ mn) 128 6,788 119 5,591 4,640 112 110 108 2,781 2,120 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.5 26% 27% 27% 26% 0.4 28% 24% 19% 18% 19% 0.1 0.01 0.02 FY 15
Slide 17: Shareholder Information
Shareholder Information Stock Data (As on 08th August 2019) Top 5 Institutional Holders (As on 02nd August 2019) Institutions OS (%) Market Capitalization (₹) 17,666 mn ORBIMED ASIA III MAURITIUS 12.09 HDFC SMALL CAP FUND 3.89 Shares Outstanding 111.6 mn HDFC TRUSTEE COMPANY LTD. A/C HDFC 2.32 Free
Slide 18: Thank You
Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica Thank You LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159 Email: investor.realtions@advancedenzymes.com
Advanced Enzyme Technologies — Q2 FY2020 Earnings Presentation on 6ix